Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.47 |
| ▸ | PPARA | Q07869 | 13/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479355 | 1.00 | PPARG (0.47) | PPARGPPARAPPARDCA12CA1 | |
| SCHEMBL5479352 | 1.00 | PPARG (0.47) | PPARGPPARAPPARDCA12CA1 | |
| SCHEMBL5374852 | 0.90 | PPARG (0.46) | PPARGPPARAPPARD | |
| SCHEMBL5989805 | 0.88 | NLRP3 (0.42) | PPARGPPARACA12CA1CA2 | |
| SCHEMBL4332255 | 0.86 | GRIA2 (0.42) | PPARGPPARACA12CA1CA2 | |
| SCHEMBL4332258 | 0.86 | GRIA2 (0.42) | PPARGPPARACA12CA1CA2 | |
| SCHEMBL4081032 | 0.84 | PPARG (0.44) | PPARGPPARAPPARD | |
| SCHEMBL4327324 | 0.83 | CYP4F2 (0.47) | PPARGPPARAPPARD | |
| SCHEMBL3541115 | 0.83 | MMP8 (0.56) | PPARGPPARAPPARD | |
| SCHEMBL27546630 | 0.83 | MMP8 (0.56) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | IRM LLC (BM) | 2008-11-27 | — | — | US | disclosed |
| EP-1945633-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056497-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| US-7202213-B2 | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARG 22/4885PPARA 11/4885PPARD 8/4885 |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARG 47/4885PPARA 74/4885PPARD 60/4885 |
| US-20080292608-A1 | Compounds and Compositions as Ppar Modulators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.